Sands Capital Management LLC Upped Its Alexion Pharmaceuticals INC (ALXN) Position by $41.42 Million as Stock Value Declined

July 17, 2017 - By Henry Gaston

Investors sentiment is 1.07 in Q4 2016. Its the same as in 2016Q3. It is the same, as 59 investors sold ALXN shares while 167 reduced holdings. only 81 funds opened positions while 160 raised stakes. 215.83 million shares or 2.26% more from 211.05 million shares in 2016Q3 were reported. Grandfield & Dodd Ltd has 3,223 shares for 0.05% of their portfolio. Polar Capital Llp holds 461,150 shares or 0.9% of its portfolio. Blackrock Japan holds 0.12% or 299,847 shares in its portfolio. Moreover, Schwab Charles Investment Mngmt has 0.09% invested in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN). Credit Suisse Ag has invested 0.06% in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN). Partner Investment Management LP reported 0.62% in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN). Atalanta Sosnoff holds 1,660 shares. Wetherby Asset Management invested 0.28% of its portfolio in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN). Meag Munich Ergo Kapitalanlagegesellschaft Mbh invested in 23,926 shares or 0.14% of the stock. Fayez Sarofim And owns 12,950 shares or 0.01% of their US portfolio. Australia-based Westpac Bk has invested 0% in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN). Carlson Capital LP owns 104,617 shares. Fincl Bank Of Nova Scotia has invested 0% in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN). Susquehanna Int Gru Llp stated it has 0.02% of its portfolio in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN). Utah Retirement Sys reported 0.12% stake.

Since February 6, 2017, it had 4 insider buys, and 23 insider sales for $230.27 million activity. Shares for $131,357 were sold by Miller Edward. HANTSON LUDWIG bought $1.17M worth of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) on Wednesday, June 14. Another trade for 994 shares valued at $130,856 was made by Wagner Heidi L on Monday, February 27. 835 shares were sold by PARVEN ALVIN S, worth $97,511. MACKAY MARTIN also sold $27,524 worth of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) on Thursday, February 9. O’Neill Julie sold $87,104 worth of stock or 651 shares. $449,135 worth of stock was sold by Carmichael Clare on Monday, February 6.

Sands Capital Management Llc increased its stake in Alexion Pharmaceuticals Inc (ALXN) by 6.47% based on its latest 2016Q4 regulatory filing with the SEC. Sands Capital Management Llc bought 339,516 shares as the company’s stock declined 11.63% while stock markets rallied. The institutional investor held 5.59M shares of the health care company at the end of 2016Q4, valued at $683.36M, up from 5.25M at the end of the previous reported quarter. Sands Capital Management Llc who had been investing in Alexion Pharmaceuticals Inc for a number of months, seems to be bullish on the $28.34 billion market cap company. The stock declined 0.24% or $0.3 reaching $126.41 on the news. About 529,112 shares traded. Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) has declined 18.12% since July 17, 2016 and is downtrending. It has underperformed by 34.82% the S&P500.

Sands Capital Management Llc, which manages about $42.07 billion and $28.70 billion US Long portfolio, decreased its stake in Palo Alto Networks Inc (NYSE:PANW) by 498,287 shares to 3.81 million shares, valued at $476.07 million in 2016Q4, according to the filing. It also reduced its holding in Salesforce Com Inc (NYSE:CRM) by 4.49M shares in the quarter, leaving it with 16.67 million shares, and cut its stake in Monsanto Co (NYSE:MON).

More notable recent Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) news were published by: Nasdaq.com which released: “Alexion Pharma: CHMP Issues Positive Opinion For Soliris – Quick Facts” on June 23, 2017, also Benzinga.com with their article: “Exclusive: Alexion Responds To Government Probe” published on July 06, 2017, Gurufocus.com published: “Factory Mutual Insurance Co Buys Alexion Pharmaceuticals Inc, SPDR Series …” on July 10, 2017. More interesting news about Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) were released by: Barrons.com and their article: “Alexion Pharmaceuticals: Nothing to See Here?” published on July 07, 2017 as well as Seekingalpha.com‘s news article titled: “Alexion higher after posting Strensiq update” with publication date: July 05, 2017.

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) Ratings Coverage

Among 24 analysts covering Alexion Pharmaceuticals Inc. (NASDAQ:ALXN), 17 have Buy rating, 0 Sell and 7 Hold. Therefore 71% are positive. Alexion Pharmaceuticals Inc. had 57 analyst reports since July 27, 2015 according to SRatingsIntel. On Thursday, December 22 the stock rating was maintained by RBC Capital Markets with “Outperform”. The firm has “Outperform” rating given on Monday, July 11 by Credit Suisse. The firm has “Outperform” rating by BMO Capital Markets given on Friday, April 29. Stifel Nicolaus maintained Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) rating on Friday, December 11. Stifel Nicolaus has “Buy” rating and $245 target. Barclays Capital maintained Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) on Friday, July 29 with “Equal-Weight” rating. The stock has “Buy” rating by Stifel Nicolaus on Friday, July 29. Morgan Stanley downgraded Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) on Tuesday, December 13 to “Equal-Weight” rating. The company was downgraded on Thursday, January 7 by BTIG Research. Vetr upgraded the stock to “Buy” rating in Wednesday, August 12 report. On Thursday, January 7 the stock rating was initiated by SunTrust with “Buy”.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.


Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: